Matthew B. Palmer, MD, PhD

Pathology and Laboratory Medicine
Accepting new patients
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Penn Medicine Provider

About me

  • Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: Emory University
  • Residency: Yale University School of Medicine
  • Fellowship: Yale University School of Medicine

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Palmer is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Mohandes S, Fakhreddine M, Sheng H, Al Dulaimee M, Mottl A, Scialla J, Almaani S, Luciano R, Isakova T, Bansal S, Argyropoulos C, Avasare R, Singh M, Campbell KN, Townsend R, Coppock G, Palmer M, Susztak K; TRIDENT Consortium. Percutaneous Native Kidney Biopsy Complications in Diabetic Patients in the TRIDENT Cohort , Clinical Journal of the American Society of Nephrology: 2026


Bhoj VG, Kaminski M, Zhao H, Jackson K, Wang W, Liu C, Montgomery RA, Ali N, Mangiola M, Spitzer TR, Safa K, Pattanayak V, Taj R, Chiu J, Bui TM, Sonnenberg EM, Markmann JF, Milone MC, June CH, Siegel DL, Fraietta JA, Gonzalez V, Locci M, Palmer M, Monos D, Hwang WT, Sledge T, Bridges ND, Goldstein JS, Odim J, Sweet SC, Besharatian BD, Hussain SM, Brown NK, Kamoun M, Garfall AL, Naji A. Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy. , New England Journal of Medicine, 394(21): 2026,2117-2125


Dumoulin B, Levinsohn J, Klötzer KA, Li C, Mao L, Ha E, Mohandes S, Nguyen T, Paruzzo L, Hirohama D, Fang V, Bhoj VG, Parhiz H, Andrade-Silva M, Abedini A, Bergeson A, Traum D, May MJ, Kaestner KH, Ruella M, McAllister FE, Hakimi AA, Li M, Palmer M, Wherry EJ, Hunter CA, Cancro MP; TRIDENT consortium; Susztak K. Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup. , Nature, 653(8116): 2026,1158-1169


Kim H, Golla M, Gullipalli D, Halle W, Miwa T, Palmer M, Song WC. Treatment of atypical hemolytic uremic syndrome and C3 glomerulopathy in mice by hepatic expression of factor D , Blood Advances, 10(6): 2026,2024-2037


Cohen IJ, Bochi-Layec AC, Lemoine J, Jenks S, Bayat P, Kim KH, Zhao H, Ugwuanyi O, Stella F, Ghilardi G, Gabrielli G, McCuaig S, Iatrou A, Vlachonikola E, Karipidou M, Bouziani E, Espie D, Ramasubramanian R, Agathangelidis A, Bhosale A, Paruzzo L, Medico G, Kolar B, Bugrovsky R, Guruprasad P, Wang LP, Harris J, Arons E, Zhang Y, Pajarillo R, Kreiger PA, Day CP, Sahinalp SC, Wu CH, Santi A, Fulmer B, Cases M, Palmer MB, Porazzi P, Wherry EJ, Kreitman RJ, Tiacci E, Apostolidis SA, Behrens EM, Bhoj V, Sanz I, Inghirami G, Schuster SJ, Ghia P, Stamatopoulos K, Ruella M. Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. , Science Translational Medicine, 18(835): 2026


Pandit K, Coudray N, Quiros AC, Surapaneni A, Upadhyay D, Vanguri RS, Hirohama D, Mohandes S, Schlosser P, Thiessen-Philbrook H, Wen Y, Parikh CR, Rhee EP, Waikar SS, Schmidt I, Rosenberg AZ, Palmer MB, Susztak K, Grams ME, Tsirigos A; TRIDENT Study Investigators Unbiased self supervised learning of kidney histology reveals phenotypic and prognostic insights , Scientific Reports, 15(1): 2025,35131


Dhanunjay Mukhi, Lakshmi Prasanna Kolligundla, Tomohito Doke, Magaiver Andrade- Silva, Hongbo Liu, Matthew Palmer, Katalin Susztak The actin and microtubule network regulator WHAMM is identified as a key kidney disease risk gene. , Cell Reports, 44(4): 2025


Aguila T, Madan R, Palmer MB, Derk CT Zebra Bodies in Kidney Biopsy: Drug-Induced Phospholipidosis in a Patient With Systemic Lupus Erythematosus. , Journal of Rheumatology: 2025


Liu H, Abedini A, Ha E, Ma Z, Sheng X, Dumoulin B, Qiu C, Aranyi T, Li S, Dittrich N, Chen HC, Tao R, Tarng DC, Hsieh FJ, Chen SA, Yang SF, Lee MY, Kwok PY, Wu JY, Chen CH, Khan A, Limdi NA, Wei WQ, Walunas TL, Karlson EW, Kenny EE, Luo Y, Kottyan L, Connolly JJ, Jarvik GP, Weng C, Shang N, Cole JB, Mercader JM, Mandla R, Majarian TD, Florez JC, Haas ME, Lotta LA; Regeneron Genetics Center‡; GHS-RGC DiscovEHR Collaboration§; Drivas TG; Penn Medicine BioBank¶; Vy HMT, Nadkarni GN, Wiley LK, Wilson MP, Gignoux CR, Rasheed H, Thomas LF, Åsvold BO, Brumpton BM, Hallan SI, Hveem K, Zheng J, Hellwege JN, Zawistowski M, Zöllner S, Franceschini N, Hu H, Zhou J, Kiryluk K, Ritchie MD, Palmer M, Edwards TL, Voight BF, Hung AM, Susztak K Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants. , Science, 387(6734): 2025,4753


Sato S, Miwa T, Gullipalli D, Golla M, Mohammadyari E, Zhou L, Palmer M, Song WC. Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1-5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy. , Immunohorizons, 9(3): 2025